Harrington Robert Arthur 4
Research Summary
AI-generated summary
CYTOKINETICS Director Robert Harrington Receives 191-Share Award
What Happened
Robert Arthur Harrington, a director of CYTOKINETICS INC (CYTK), was issued 191 shares of common stock under the company's Director Equity in Lieu of Cash Retainer Program. The shares were reported at $65.37 each for a total value of $12,486. This transaction is an award/acquisition (code A), not an open-market purchase or sale.
Key Details
- Transaction date: 2026-04-15; Price per share: $65.37; Total value: $12,486.
- Transaction type: Award/Grant (SEC code A). Shares are fully vested per filing footnote.
- Shares owned after the transaction: Not reported on this Form 4.
- Filing timeliness: Reported on 2026-04-15 (same day as the transaction); no late filing indicated.
- Footnote: Shares granted pursuant to Director Equity in Lieu of Cash Retainer Program; fully vested.
Context
- This was a compensation award to a director rather than a market buy or sale, so it reflects compensation mechanics rather than an explicit trading signal.
- Fully vested shares mean Harrington has immediate ownership and control of the shares.